ARTICLE | Clinical News
ParvOryx: Phase I/IIa data
July 13, 2015 7:00 AM UTC
The open-label, German Phase I/IIa ParvOryx01 trial in 18 patients with progressive primary or recurrent glioblastoma showed that ParvOryx was safe and induced “strong” cellular immune responses. ...